Spataru, Amalia
van Dommelen, Paula http://orcid.org/0000-0001-5546-6244
Arnaud, Lilian
Le Masne, Quentin
Quarteroni, Silvia
Koledova, Ekaterina
Article History
Received: 6 October 2021
Accepted: 31 May 2022
First Online: 6 July 2022
Declarations
:
: Ethics approval was not required for this analysis, since we used secondary anonymized data from a commercially available service that collected data outside the scope of this study. The aforementioned commercial service had received all necessary legal approvals to allow secondary research purposes. All methods were performed in accordance with the relevant guidelines and regulations. The data was collected and analyzed according to the informed consent which was obtained at the time of data collection by the commercial service and provided without a patient identifier. The informed consent specifically allowed the use of data for secondary analysis and it was locally approved by legal teams and Data Privacy Officers. Administrative permissions for secondary data use were granted by the Data Privacy Officer of Ares Trading S.A. (an affiliate of Merck KGaA) at the time and the Application Owner, Quentin Le Masne (who is a co-author on this manuscript).
: Not applicable.
: AS, PvD, and SQ have consultancy agreements with Merck. LA and QLM are employees of Ares Trading S.A., an affiliate of Merck KGaA. EK is an employee of Merck Healthcare KGaA, Darmstadt, Germany and holds shares in the company.